Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

An Efficacy and Safety Study of Intravenous Pantoprazole in the Prevention of Recurrent Peptic Ulcer Bleeding After Successful Hemostasis

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00040495

Enrollment

149

Registered

2002-06-28

Start date

2001-04-30

Completion date

2003-01-31

Last updated

2013-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peptic Ulcer Hemorrhage

Keywords

Peptic, Ulcer, Hemorrhage

Brief summary

The purpose of this study is to evaluate the efficacy and safety of intravenous pantoprazole in the prevention of rebleeding in patients with bleeding peptic ulcer disease after successful endoscopic hemostatic therapy.

Interventions

DRUGPantoprazole

Study design

Primary purpose

PREVENTION

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients must be men or non-pregnant women at least 18 years of age * Patients who present with a gastric or duodenal ulcer

Exclusion criteria

* Patients with ulcer appearance of clean base (non-oozing, non-spurting) or flat pigmented spot; adherent clots not removed by irrigation * Patients presenting with active bleeding and/or NBVV at 2 or more separate sites * Patients with any severe concomitant diseases, eg, end stage liver or renal disease, or unstable cardiovascular, pulmonary, renal, hepatic, or gastrointestinal diseases

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026